이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Onconetix 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ralph Schiess

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	1.7yrs

최근 관리 업데이트

Recent updates

CEO

Ralph Schiess (45 yo)

less than a year

테뉴어

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ralph Schiess	Interim CEO & Chief Science Officer	less than a year	데이터 없음	데이터 없음
Karina Fedasz	Interim Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Brian Price	Head of Technology Strategy	4yrs	US$126.48k	데이터 없음
Frank Jaeger	Senior VP of Marketing & Business Development	1.6yrs	데이터 없음	데이터 없음
Andrew Skibo	Global Head of Biologics Operations	3.3yrs	데이터 없음	데이터 없음
Theodore Yoho	Head of Business Development	3.3yrs	데이터 없음	데이터 없음
Ali Fattom	Head of Science & Discovery	2yrs	데이터 없음	데이터 없음
Jay Newmark	Chief Medical Officer	1.4yrs	데이터 없음	데이터 없음
Christian Bruhlmann	Chief Strategy Officer & GM of Europe	less than a year	데이터 없음	데이터 없음
Donald Very	Senior VP of Commercial Research & Development	no data	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: J4T 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Rice	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Thomas Meier	Director	less than a year	데이터 없음	데이터 없음
James Sapirstein	Non Executive Chairman & Lead Independent Director	2.6yrs	US$182.12k	데이터 없음
Ajit Singh	Independent Director	less than a year	데이터 없음	데이터 없음
Sunetra Gupta	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Simon Tarsh	Independent Director	2.1yrs	US$112.62k	데이터 없음
Timothy Ramdeen	Independent Non-Executive Director	1.7yrs	US$82.67k	데이터 없음

1.7yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: J4T 의 이사회는 경험(평균 재직 기간 1.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Onconetix 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Recent updates

Onconetix Provides Non-Compliance Update

Onconetix, Inc. announced that it expects to receive $5 million in funding

Onconetix, Inc. announced delayed 10-Q filing

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

New major risk - Financial position

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

High number of new and inexperienced directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

CEO, President & Executive Chairman recently sold €2.7m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령